CELL & GENE THERAPY INSIGHTS

Viral vector bioprocessing

Guest Editor:
Anindya Dasgupta, Director, Vector Development at Expression Therapeutics
Anindya Dasgupta
Director, Vector Development at Expression Therapeutics
<p>Anindya is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina, USA. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta, USA, were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of gamma delta; T cells in serum free media. Anindya is a co-inventor of a patent on anti-cancer strategy. At his recent role at Cincinnati Childrens Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.</p>
April 2021

  • Simplifying AAV protein analytics with Maurice

    Simplifying AAV protein analytics with Maurice

    29 April 2021
    FastFacts
    Chris Heger PhD
    Chris Heger PhD
    Director, Applications Science
    Chris Heger, Senior Manager of Applications Science for the Analytical Solutions Division of Bio-Techne, leads a team chartered with creating scientific collateral, fostering collaborations, training, and coming up with new applications. Chris has expertise in immunoassays, capillary electrophoresis, antibody design and production, and chromatography. In recent years, his team has focused on developing analytical solutions for cell and gene therapy researchers.Chris received his doctoral degree in Pharmacology from Cornell University and completed his post-doctoral training at the National Cancer Institute. Working in the Antibody and Protein Purification Unit, Chris oversaw antibody development projects, from immunogen design to final product. A unique aspect of his postdoctoral training was his role in the evaluation of new technologies, serving as the gateway for cutting edge instrumentation to get into use at the NCI/NIH. Through this role, Chris became well-acquainted with ProteinSimple and after completing his postdoctoral training, began working for ProteinSimple (now part of Bio-Techne).
  • Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

    H Ihre,
    Henrik Ihre, PhD
    Director Strategic Technologies, Cytiva
    Henrik Ihre has his roots in biopharma, leadership and product development for the biopharma downstream industry in specific. He is motivated by bringing new solutions and manufacturing of new pharmaceuticals for patients developed by partners of Cytiva. He has been the Director of Strategic Technologies since March 2020 with specific knowledge and background in the downstream purification of biopharmaceuticals for over 20 years. 
    P Guterstam,
    Peter Guterstam, MD
    Product Manager, Next Generation Resins & Technologies, Cytiva
    Peter is Global Product Manager at Cytiva with responsibility for products tailored for downstream processing of Advanced Therapy Medicinal Products. He is based in Uppsala, Sweden. Peter earned is PhD in Neurochemistry from Stockholm University in 2009. He has been with GE since 2003, primarily working in various roles associated with oligonucleotide synthesis and purification. Since GE’s acquisition of Puridify, Peter has the business responsibility to develop products based on the Fibro technology to complement Cytiva’s portfolio of chromatography resins and to develop it further to generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.
    M Lundgren
    Mats Lundgren, PhD
    Customer Applications Director, Life Sciences, GE Healthcare, Sweden
    Mats has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK. In his industrial career Mats has had positions as scientist, team manager and Vice President at Pharmacia, AstraZeneca and smaller biotech companies.  In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company.  In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.
    4 August 2021
    Innovator Insight
  • The EuLV system: lentiviral vector production based on stable producer cell lines

    R Liu
    Roy Bin Liu
    Business Development Director
    Roy Bin Liu Business Development Director, EurekaBio. Mr Liu graduated from the Hong Kong University of Science and Technology with a Masters degree in Biotechnology. He previously worked in Bio-techne and InvivoGen. Mr Liu joined Eureka Bio in 2016, and has extensive knowledge of the cell and gene therapy industry, and is experienced in business development, project management, process development, cGMP etc.
    21 April 2021
    FastFacts
  • Scalable, single-use technologies for purification of lentiviral vectors

    T Sanderson
    Todd Sanderson
    Senior Manager – R&D Bioprocessing Group, Pall Corporation
    Todd has been with Pall since 2006. He has over 20 years of research experience with expertise in mammalian cell culture, process development and analytical method development. He currently leads the US team of Upstream and Analytics within the R&D Bioprocessing Group. He holds a B.S. in Biochemistry and B.S. in Psychology from Michigan State University. When not at work, Todd enjoys gardening and spending time with his young children
    29 April 2021
    FastFacts
  • Cell and gene manufacturing: a case study approach to overcoming challenges

    S Werner
    Sean Werner
    President, Sexton Biotechnologies
    Sean Werner, Presidnet, Sexton Biotechnologies. A manufacturer or processing and handling tools and reagents for the development and manufacture of cell and gene therapies. Sean received his PhD from Purdue University in Biology followed by post- doctoral positions at the Indiana University School of Medicine and Eli Lilly. Prior to his current role he spent 11 years with Cook Medical and Cook Regentec filling various roles in the global regulatory and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 15 years working in the life science industry, he has guided pre-clinical and clinical testing and submission strategies leading to global commercialization of multiple medical devices and bioprocessing tools.  
    29 April 2021
    FastFacts
  • Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

    Improving upon legacy vector and plasmid bioprocess technology for tomorrow’s advanced therapies

    Mats Lundgren
    Mats Lundgren, Customer Applications Director, Life Sciences, Cytiva
    Peter Guterstam
    Peter Guterstam, Product Manager, Next Generation Resins & Technologies, Cytiva
    Henrik Ihre
    Henrik Ihre, Director Strategic Technologies, Cytiva
    18 May 2021
    Webinar
  • Simplifying AAV protein analytics with Maurice

    C Heger
    Chris Heger PhD
    Director, Applications Science
    Chris Heger, Senior Manager of Applications Science for the Analytical Solutions Division of Bio-Techne, leads a team chartered with creating scientific collateral, fostering collaborations, training, and coming up with new applications. Chris has expertise in immunoassays, capillary electrophoresis, antibody design and production, and chromatography. In recent years, his team has focused on developing analytical solutions for cell and gene therapy researchers.Chris received his doctoral degree in Pharmacology from Cornell University and completed his post-doctoral training at the National Cancer Institute. Working in the Antibody and Protein Purification Unit, Chris oversaw antibody development projects, from immunogen design to final product. A unique aspect of his postdoctoral training was his role in the evaluation of new technologies, serving as the gateway for cutting edge instrumentation to get into use at the NCI/NIH. Through this role, Chris became well-acquainted with ProteinSimple and after completing his postdoctoral training, began working for ProteinSimple (now part of Bio-Techne).
    29 April 2021
    FastFacts
  • Current and future perspectives on lentiviral vector bioprocess and bioanalytical tools

    P Carter
    Paul Carter
    Head of Vector Processing at Quell Therapeutics
    Paul Carter is the Head of Vector Processing at Quell Therapeutics Limited and has over 30 years’ experience in the pharmaceutical industry, working across cell and gene therapy, biopharmaceutical and small molecule R&D. Prior to joining Quell, he was leading GSK’s Downstream Process Development Group in Cell and Gene Therapy.
    4 May 2021
    Interview
  • Gammaretroviral and lentiviral vector manufacture: brief overview

    R Sengupta
    Ranjita Sengupta
    Adicet Bio, 200 Constitution Drive, Menlo Park, CA-94025, USA
    29 April 2021
    Expert Insight
  • Yesterday, today and tomorrow: the evolving landscape of gene therapy manufacturing and process development

    D Knop
    David R Knop, PhD
    Vice President of Process Development, AGTC
    29 April 2021
    Commentary
  • Making the move from antibody therapeutics to gene therapy: applicability of monoclonal antibody learnings to adeno-associated virus vector bioprocessing

    A Tustian
    Andrew D Tustian
    Regeneron Pharmaceuticals Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA andrew.tustian@regeneron.com
    29 April 2021
    Commentary
  • Facilitating gene therapy development with solutions to four capsid analytical challenges

    S Darling
    Susan Darling
    Senior Director Product Management, Market Management, CE and Biopharma, SCIEX
    29 April 2021
    Innovator Insight
  • Keys to success for in-house lentiviral vector tech transfer and manufacture

    N Nuñez,
    Nicole Nuñez
    Regulatory Scientist, Eureka Therapeutics
    Nicole Nuñez, PhD, joined Eureka Therapeutics in 2018 as a Process Development Scientist, and co-led the process development, manufacture, tech transfer, vendor management and regulatory compliance of lentiviral vectors to be used in the production of T-cell based therapies. Nicole currently serves Eureka as a Regulatory Scientist focusing on the development and implementation of regulatory strategy for the company’s T-cell therapy and vector products.
    L Powers
    Liam Powers
    Process Development Research Associate, Eureka Therapeutics
    Liam Powers joined Eureka Therapeutics as an intern in 2016 and is currently a Process Development Research Associate. His main focus has been the optimization and development of lentiviral vector production and purification systems. He led the engineering of Eureka’s GMP vector process and provided oversight in tech transfer and manufacturing operations.
    29 April 2021
    Interview
  • Improving AAV vector manufacture: a question of scale

    S Wissing,
    Silke Wissing
    Chief Scientific Officer, Cevec Pharmaceuticals
    Dr Silke Wissing has wide-ranging experience in the fields of virology, cell biology and cell line development, as well as molecular biology. Before joining CEVEC in 2011, she held a position as a group leader in the Gladstone Institute for Virology and Immunology, San Francisco, where she performed research in the field of HIV-1 biology, stem cell research and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from the University of Tübingen.
    J Coronel,
    Juliana Coronel
    Head of Upstream Process Development, Cevec Pharmaceuticals
    J Wölfel et al.
    Jans Wölfel
    Head of Downstream Processing and Analytics, Cevec Pharmaceuticals
    29 April 2021
    Interview
  • How fixed bed bioreactors are changing the game for adherent cell culture-based vector production

    T Upton,
    Todd Upton
    Innovation Portfolio Senior Manager, Corning Research & Development Corporation
    Todd Upton is a senior program manager at Corning Life Sciences. He has more than 25 years of experience developing biotechnology products for use in life sciences businesses, including 17 years at Corning. Prior to joining Corning, Todd was a senior researcher at Cytomatrix, LLC where he developed a novel bioreactor platform utilizing a rigid matrix for the large-scale culture of adherent cells. He also helped develop novel culture platforms for Hematopoietic stem cells. Todd holds a Ph.D. in Molecular Biology and Biochemistry from the University of Connecticut.
    V Goral
    Vasiliy Goral
    Research & Development Associate, Corning Research & Development Corporation
    Vasiliy Goral is a research & development associate at the Corning Research & Development Corporation. He has 18 years of experience developing biotechnology products for use in life sciences businesses, including 14 years at Corning. Prior to joining Corning, Vasiliy was a senior researcher at Innovative Biotechnologies International, Inc., where he developed a microfluidic biosensor platform with applications in multiple markets such as point-of-care testing, national defense, and food/water testing. Vasiliy holds a PhD in chemistry from Moscow State University.
    29 April 2021
    Interview
  • Efficient and scalable purification of mRNA using affinity chromatography

    Z Gulyas
    Zoltan Gulyas
    Field Applications Specialist, Purification, Thermo Fisher Scientific
    Zoltan has a MSc degree in chemical engineering, and graduated from the University of Technology and Economics in Budapest, Hungary. He started his career with Gedeon Richter Plc. in Budapest as a process development scientist, where his main responsibility was to develop purification methods for small molecular pharmaceuticals using preparative scale HPLC. After 3 years he joined the biologics development team to purity recombinant proteins and monoclonal antibodies. During his 5 years as DSP scientist Zoltan gathered experience in process development, scale-up, technology transfer, process validation, manufacturing and filing of biologics. In 2017 he joined Thermo Fisher Scientific as a Field Applications Specialist for Purification covering primarily Northern Europe, and he has been supporting the use of POROS and CaputreSelect products for recombinant proteins, Mabs and derivatives, viral vectors and accines for past 3 years.  
    29 April 2021
    FastFacts
  • The Corning® Ascent Fixed Bed Reactor (FBR) System: Designed for high yield, scalable viral vector production & other applications for cell & gene therapies.

    Z Melkoumian
    Zara Melkoumian
    Senior Technology Manager, Corning Research and Development Corporation
    Zara holds a PhD in Pharmacology and Toxicology and has 15 years of industry experience in bringing innovative cell culture products and technologies to market. Prior to joining Corning, Zara was a post-doctoral fellow at Cornell University where she studied the mechanism of action of a novel tumor suppressor gene in human breast cancer cells.
    29 April 2021
    FastFacts
  • Improving AAV vector manufacture: a question of scale

    S Wissing,
    Silke Wissing
    Chief Scientific Officer, Cevec Pharmaceuticals
    Dr Silke Wissing has wide-ranging experience in the fields of virology, cell biology and cell line development, as well as molecular biology. Before joining CEVEC in 2011, she held a position as a group leader in the Gladstone Institute for Virology and Immunology, San Francisco, where she performed research in the field of HIV-1 biology, stem cell research and cell line development. Dr. Silke Wissing holds a PhD in Biochemistry from the University of Tübingen.
    J Coronel,
    Juliana Coronel
    Head of Upstream Process Development, Cevec Pharmaceuticals
    J Wölfel et al.
    Jens Wölfel
    Head of DSP and Analytics at CEVEC Pharmaceuticals
    29 April 2021
    Podcast
  • Key considerations for maximizing LV and AAV production in transient transfection workflows

    Key considerations for maximizing LV and AAV production in transient transfection workflows

    Leisha Kopp
    Leisha Kopp, Applications Scientist, Mirus Bio LLC
    Dr. Beth Larimore
    Dr. Beth Larimore, Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc
    Anindya Dasgupta
    Anindya Dasgupta, Director of Vector Development, Expression Therapeutics
    Nolan Sutherland
    Nolan Sutherland, Scientist, Bluebird Bio
    9 June 2021
    Webinar
  • Scalable suspension LVV production platforms for cell and gene therapy

    Scalable suspension LVV production platforms for cell and gene therapy

    Suparna Sanyal
    Suparna Sanyal, Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec
    Michael Haller
    Michael Haller, Senior R&D Scientist, Viral Vector Process Development, Lonza Pharma & Biotec
    Young Shin
    Young Shin, R&D Principal Scientist, Cell & Gene Technologies, Lonza Pharma & Biotec
    13 April 2021
    Webinar